With 0.17 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.36 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.0800 whereas the lowest price it dropped to was $1.0200. The 52-week range on CLNN shows that it touched its highest point at $6.12 and its lowest point at $0.87 during that stretch. It currently has a 1-year price target of $9.17. Beta for the stock currently stands at 0.15.
Price Performance and Earnings:
Three-month performance dropped to -67.79% while six-month performance fell -55.51%. The stock lost -78.57% in the past year, while it has lost -74.39% so far this year. A look at the trailing 12-month EPS for CLNN yields -0.39 with Next year EPS estimates of -0.57. For the next quarter, that number is -0.13. This implies an EPS growth rate of 85.60% for this year and 3.40% for next year.
Float and Shares Shorts:
At present, 63.51 million CLNN shares are outstanding with a float of 27.20 million shares on hand for trading. On Oct 30, 2022, short shares totaled 3.38 million, which was 5.31% higher than short shares on Sep 29, 2022. In addition to Mr. Robert Etherington MBA as the firm’s CEO, Pres & Director, Mr. Mark G. Mortenson serves as its Co-Founder & Chief Science Officer.
Through their ownership of 6.01% of CLNN’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 54.90% of CLNN, in contrast to 4.88% held by mutual funds. Shares owned by individuals account for 1.94%. As the largest shareholder in CLNN with 1.73% of the stake, Tang Capital Management LLC holds 1,100,000 shares worth 1,100,000. A second-largest stockholder of CLNN, The Vanguard Group, Inc., holds 923,844 shares, controlling over 1.46% of the firm’s shares. Kepos Capital LP is the third largest shareholder in CLNN, holding 400,000 shares or 0.63% stake. With a 0.93% stake in CLNN, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 592,311 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.45% of CLNN stock, is the second-largest Mutual Fund holder. It holds 288,123 shares valued at 0.83 million. Fidelity Extended Market Index Fu holds 0.17% of the stake in CLNN, owning 107,646 shares worth 0.31 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, CLNN reported revenue of $35.00k and operating income of -$12.97M. The EBITDA in the recently reported quarter was -$12.89M and diluted EPS was -$0.07.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CLNN since 7 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CLNN analysts setting a high price target of $15.00 and a low target of $4.00, the average target price over the next 12 months is $9.17. Based on these targets, CLNN could surge 1328.57% to reach the target high and rise by 280.95% to reach the target low. Reaching the average price target will result in a growth of 773.33% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CLNN will report FY 2022 earnings on 03/27/2023. Analysts have provided yearly estimates in a range of -$0.51 being high and -$0.68 being low. For CLNN, this leads to a yearly average estimate of -$0.60. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Clene Inc. surprised analysts by $0.05 when it reported -$0.17 EPS against a consensus estimate of -$0.22. The surprise factor in the prior quarter was $0.13. Based on analyst estimates, the high estimate for the next quarter is -$0.08 and the low estimate is -$0.19. The average estimate for the next quarter is thus -$0.13.
Summary of Insider Activity:
Insiders traded CLNN stock several times over the past three months with 4 Buys and 0 Sells. In these transactions, 5,000,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 32 while that of sell transactions has risen to 6 over the past year. The total number of shares bought during that period was 11,261,165 while 464,508 shares were sold.